These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12039395

  • 1. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
    Asano T, Saito Y, Kawakami M, Yamada N, Fidarestat Clinical Pharmacology Study Group.
    J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T.
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 May; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 5. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N.
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [Abstract] [Full Text] [Related]

  • 6. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
    Takiguchi Y, Wada K, Nakashima M.
    Eur J Pharmacol; 1992 May 14; 215(2-3):289-91. PubMed ID: 1396993
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
    Nakano I, Tsugawa T, Shinohara R, Watanabe F, Fujita T, Nagata M, Kato T, Himeno Y, Kobayashi T, Fujiwara K, Nagata M, Itoh M, Nagasaka A.
    J Diabetes Complications; 2003 May 14; 17(6):337-42. PubMed ID: 14583178
    [Abstract] [Full Text] [Related]

  • 10. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
    Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N.
    Life Sci; 1995 May 14; 57(1):23-9. PubMed ID: 7596218
    [Abstract] [Full Text] [Related]

  • 11. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct 14; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils.
    Suzuki K, Kawamura T, Sakakibara F, Sasaki H, Sano T, Sakamoto N, Hotta N.
    Diabet Med; 1999 Jan 14; 16(1):67-73. PubMed ID: 10229296
    [Abstract] [Full Text] [Related]

  • 14. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J, Gao HX, Yang N, Zhu XD, Sun RB, Xie Y, Zeng CH, Zhang JW, Wang JK, Ding F, Aa JY, Wang GJ.
    Acta Pharmacol Sin; 2019 Jan 14; 40(1):86-97. PubMed ID: 29930278
    [Abstract] [Full Text] [Related]

  • 15. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D, Kusunoki M, Shinzawa G, Feng Z, Nishina A, Nakamura T.
    Auton Neurosci; 2015 Dec 14; 193():69-73. PubMed ID: 26272532
    [Abstract] [Full Text] [Related]

  • 16. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct 14; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K, Sato N, Sato K, Shimizu H, Mori M.
    Endocrinology; 1998 Aug 14; 139(8):3404-8. PubMed ID: 9681489
    [Abstract] [Full Text] [Related]

  • 19. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R, Hayakawa N, Makino M, Nagata M, Kakizawa H, Uchimura K, Hamada M, Aono T, Fujita T, Shinohara R, Nagasaka A, Itoh M.
    Diabetes Care; 1998 Apr 14; 21(4):672-3. PubMed ID: 9571366
    [No Abstract] [Full Text] [Related]

  • 20. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb 14; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.